01 Development of Intravascular Lithotripsy for Calcified Lesions The critical limb ischemia treatment market analysis shows that intravascular lithotripsy is being used to modify heavily calcified arteries before or during revascularization procedures. The technology uses controlled sonic pressure waves to break calcium within the vessel and improve access for further treatment. This development strengthens treatment options for complex calcified lesions in critical limb ischemia.
02 Expansion of Ambulatory CLTI Revascularization Critical limb ischemia revascularization is increasingly being performed in ambulatory surgical centers and outpatient laboratories for selected patients. These settings can support shorter stays and reduce the need for prolonged hospital care after suitable procedures. This shift broadens the use of outpatient pathways in limb salvage treatment.
01 Supply chain disruptions are expected to have a substantial impact on the critical limb ischemia treatment market share, as dependence on specialized balloons, stents, catheters, atherectomy systems, guidewires, and other vascular intervention devices can create procurement delays and limit treatment options when specific products are unavailable. The market is likely to follow a V-shaped recovery pattern, as critical limb ischemia requires timely limb salvage treatment, and delayed procedures can be rescheduled rapidly once affected devices and supporting supplies become available. The market is expected to grow at a CAGR of 5.95%, but supply chain constraints could approximately lower this by 0.5 percentage points, resulting in short-term growth of around 5.45%. As supply conditions normalize through improved availability of peripheral intervention devices, diversified component sourcing, restored manufacturing capacity, and more reliable medical device distribution, critical limb ischemia treatment market growth is expected to gradually return to 5.95%.
01 The critical limb ischemia treatment market forecasts strategic investment activity driven by advanced revascularization technologies, drug-coated and bioresorbable vascular therapies, minimally invasive interventions, regenerative medicine, and innovative treatments aimed at improving limb salvage and reducing amputation risk.
02 Key Investment and Funding Activities in the Critical Limb Ischemia Treatment Market, 2025–2026 Company Value (USD) Details Aplagon USD 5.6 Million In June 2026, Aplagon received USD 5.6 million in financing from Fåhraeus Startup and Growth and the European Innovation Council Fund, alongside Finnish investors, to expand clinical development. ProVascTec USD 2.9 Million In October 2025, ProVascTec received a USD 2.9 million Enterprise Ireland Disruptive Technologies Innovation Fund grant to advance PulseCLTI, a cell-therapy treatment designed to restore blood flow in patients with critical limb ischemia, through prototype development, preclinical testing, and regulatory preparation. Aveera Medical USD 1.03 Million In August 2025, Aveera Medical received a USD 1.03 million NIH/NHLBI grant to develop its Native Deep Vein Arterialization procedure using the Boomerang System for patients with no-option chronic limb-threatening ischemia, with the goal of reducing major amputations.
01 Diabetic Foot Ulcer Burden and Ischemic Wound Healing Needs Drive Market Demand Diabetic foot ulcers associated with peripheral artery disease (PAD) increase the need to restore blood flow and support limb salvage. Treatment pathways include peripheral angioplasty, stent placement, and other endovascular therapy approaches to improve limb perfusion. Greater use of vascular treatment for these complex wounds strengthens demand for critical limb ischemia (CLI) care.Poor blood flow in ischemic limbs delays tissue repair and increases the clinical need for revascularization. Restoring circulation supports wound closure and tissue recovery in patients with advanced chronic limb-threatening ischemia (CLTI). This need strengthens the use of atherectomy, vascular intervention, and vascular surgery within cardiovascular care.
01 Contrast-Related Renal Risks and Restenosis Issues Limit Market Expansion Contrast use during endovascular therapy can increase treatment concerns for patients with impaired kidney function. These risks can restrict the use of contrast-based vascular intervention in some high-risk patients and complicate treatment planning.Restenosis after peripheral angioplasty or stent placement can reduce the durability of restored blood flow. Recurrent vessel narrowing can require repeat revascularization and additional follow-up, increasing the treatment burden in advanced peripheral artery disease (PAD).
01 Development of Vascular Imaging Platforms and Specialized Distal Intervention Devices Offer Growth Opportunities Vascular imaging and planning platforms can combine vessel images, lesion measurements, and clinical information to support treatment planning before complex endovascular therapy. Technology providers can build software that helps clinicians map diseased vessels and select suitable treatment approaches for patients with advanced blood vessel disease.Specialized pedal and tibial devices can address difficult distal vessel anatomy during lower limb interventions. Manufacturers can design dedicated peripheral vascular devices for vessel access and treatment in complex cases where standard equipment has limited suitability. This creates a focused product opportunity for vascular surgery and limb salvage programs.
01 Gaps in Wound Vascular Coordination and Concentrated CLTI Services Hinder Market Growth Fragmented coordination between wound clinics, diabetes care teams, and vascular specialists can delay referral and treatment for patients with chronic limb-threatening ischemia (CLTI). Separate care pathways can slow movement from wound assessment to revascularization and limb salvage treatment.Specialized CLTI services are concentrated in major vascular centers with advanced teams and facilities. Limited access to these centers can delay vascular intervention for patients in smaller cities and underserved regions. This uneven service distribution can restrict broader access to cardiovascular care.